GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bolt Biotherapeutics Inc (STU:6LP) » Definitions » EV-to-FCF

Bolt Biotherapeutics (STU:6LP) EV-to-FCF : 0.26 (As of Dec. 13, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bolt Biotherapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bolt Biotherapeutics's Enterprise Value is €-14.65 Mil. Bolt Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was €-56.08 Mil. Therefore, Bolt Biotherapeutics's EV-to-FCF for today is 0.26.

The historical rank and industry rank for Bolt Biotherapeutics's EV-to-FCF or its related term are showing as below:

STU:6LP' s EV-to-FCF Range Over the Past 10 Years
Min: -24.39   Med: 0.58   Max: 1.7
Current: 0.23

During the past 6 years, the highest EV-to-FCF of Bolt Biotherapeutics was 1.70. The lowest was -24.39. And the median was 0.58.

STU:6LP's EV-to-FCF is ranked better than
87.08% of 387 companies
in the Biotechnology industry
Industry Median: 8.7 vs STU:6LP: 0.23

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-13), Bolt Biotherapeutics's stock price is €0.4965. Bolt Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-1.569. Therefore, Bolt Biotherapeutics's PE Ratio (TTM) for today is At Loss.


Bolt Biotherapeutics EV-to-FCF Historical Data

The historical data trend for Bolt Biotherapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bolt Biotherapeutics EV-to-FCF Chart

Bolt Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - - -0.36 1.24 0.56

Bolt Biotherapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.81 0.56 0.29 0.41 0.18

Competitive Comparison of Bolt Biotherapeutics's EV-to-FCF

For the Biotechnology subindustry, Bolt Biotherapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bolt Biotherapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Bolt Biotherapeutics's EV-to-FCF falls into.



Bolt Biotherapeutics EV-to-FCF Calculation

Bolt Biotherapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-14.649/-56.077
=0.26

Bolt Biotherapeutics's current Enterprise Value is €-14.65 Mil.
Bolt Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-56.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bolt Biotherapeutics  (STU:6LP) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Bolt Biotherapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.4965/-1.569
=At Loss

Bolt Biotherapeutics's share price for today is €0.4965.
Bolt Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.569.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Bolt Biotherapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Bolt Biotherapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Bolt Biotherapeutics Business Description

Traded in Other Exchanges
Address
900 Chesapeake Drive, Redwood, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Bolt Biotherapeutics Headlines

No Headlines